November 2015

Failed clinical trials come at a huge cost to pharmaceutical sponsors, patients' lives, and society through impact on innovation.

With a series of recent approvals, the FDA bolstered oncologists’ armamentarium for treating patients with melanoma, soft tissue sarcoma, and pancreatic cancer.

A single molecule called DNA-PKcs may drive metastatic processes that turn cancer from a slowly growing, relatively benign disease to a killer.